OCTOBER 30, 2025 Third Quarter 2025 Earnings Call Presentation Forward Looking Statements and Non-GAAP Financial Measures Statements and information in this presentation that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are made pursuant to the "safe harbor" provisions of such Act. Forward-looking statements include, but are not limited to, statements regarding our outlook, guidance, expectations, beliefs, hopes, intentions ...

THIRD QUARTER 2025 EARNINGS CONFERENCE CALL Question & Answer Steven Basta, President & Chief Executive Officer Sanjeev Narula, Chief Financial and Business Officer Robert Breedlove, Principal Accounting Officer OCTOBER 2025 NASDAQ: PHAT Today's Agenda Business Update Steven Basta, President & Chief Executive Officer Q3 2025 Financial Results Sanjeev Narula, Chief Financial and Business Officer Closing Remarks Steven Basta, President & Chief Executive Officer 2 Safe harbor This presentation contains forward ...

Financial Performance - Q3 2025 net revenues reached $12.9 million, a 44% increase compared to $9.0 million in Q3 2024 [12] - Cash on hand remains strong at $1.3 billion, intended for investment in U S launches and pipeline development [10, 12, 15] - Net loss for Q3 2025 was $103.4 million, compared to a net income of $947.9 million in Q3 2024 [15] PYRUKYND® Commercial Progress - PYRUKYND net sales were $12.9 million in Q3 2025, compared to $12.5 million in Q2 2025 and $9.0 million in Q3 2024 [15, 20] - In the U S, 262 unique PK deficiency patients have completed prescription enrollment forms since launch [20] - There are 149 net patients on PYRUKYND treatment in the U S, including new prescriptions and treatment continuations [20] - PYRUKYND has been prescribed by 227 unique prescribers in the U S [20] Regulatory and Pipeline Advancements - PYRUKYND received SFDA approval in Saudi Arabia for thalassemia [12, 27, 28] - A positive CHMP opinion in Europe was received for PYRUKYND in thalassemia [12, 27, 28] - Enrollment is complete in the tebapivat Phase 2b trial for lower-risk MDS, with top-line data anticipated in early 2026 [12, 27]

Financial Performance - Total revenue decreased slightly by 1% year-over-year, from $2171 million in 3Q24 to $2159 million in 3Q25 [22] - Adjusted EBITDA decreased by 2% year-over-year, from $693 million in 3Q24 to $676 million in 3Q25, with a margin of 31%, down one percentage point [18, 22] - Free cash flow increased significantly by 176% year-over-year, from $93 million in 3Q24 to $257 million in 3Q25 [19, 22] - The company increased 2025 guidance for revenue, adjusted EBITDA, and free cash flow by $25 million each, to approximately $8525 billion, $2625 billion, and $1225 billion, respectively [7] Segment Results - SiriusXM segment revenue decreased by 1% year-over-year, from $1627 million in 3Q24 to $1611 million in 3Q25, driven by a 1% reduction in subscriber revenue [31, 35] - Pandora and Off-platform segment revenue increased by 1% year-over-year, from $544 million in 3Q24 to $548 million in 3Q25, driven by a 2% increase in advertising revenue [37, 41] Subscriber Trends - Self-pay net subscriber additions decreased by 40,000 in 3Q25 [7] - Self-pay monthly churn remained healthy at 16% in 3Q25 [7, 26] Cost Management - Sales and marketing expenses decreased by 15% to $176 million [8] - Transmission costs decreased by 14% to $48 million [8] - Podcast ad revenue climbed nearly 50% year-over-year [7, 50]

October 30, 2025 Stuart Bradie, President and CEO Mark Sopp, EVP and CFO Jamie DuBray, VP of Investor Relations Forward-Looking Statements The statements in this presentation that are not historical statements, including statements regarding our expectations for our future financial performance, effective tax rate, operating cash flows, contract revenues, award activity and backlog, program activity, our business strategy, business opportunities, interest expense, our plans for raising and deploying capital ...

Financial Performance - Global net sales reached approximately $12.2 billion, a 3% year-over-year increase, or 2% excluding foreign exchange impacts[11] - The Growth Portfolio net sales increased by 18%, or 17% excluding foreign exchange impacts[11] - Q3 2025 GAAP Earnings Per Share (EPS) was $1.08, while Non-GAAP EPS was $1.63, including a ($0.20) charge from Acquired IPR&D and licensing income[13] - The company is narrowing Non-GAAP EPS guidance to $6.40 - $6.60 and raising total revenues to approximately $47.5 - $48.0 billion[14] Product Performance - Opdivo global net sales were $2.532 billion, a 7% year-over-year increase, or 6% excluding foreign exchange impacts[33] - Eliquis global net sales were $3.746 billion, a 25% year-over-year increase, or 23% excluding foreign exchange impacts[44] - Reblozyl global net sales were $675 million, a 25% year-over-year decrease, or 25% decrease excluding foreign exchange impacts[39] - Breyanzi global net sales were $615 million, a 37% year-over-year increase, or 37% increase excluding foreign exchange impacts[39] Strategic Initiatives - The company is on track to pay down approximately $10 billion of debt by the end of Q2 2026, with approximately $6.7 billion achieved as of Q3 2025[55] - The company has approximately $5 billion share repurchase authorization remaining as of September 30, 2025[55]

Earnings Presentation Q3 2025 Results October 30, 2025 Forward-Looking Statements This presentation and other written or oral statements made from time to time by management contain "forward looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and involve certain risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "will", "would", "could", "can", "should", "targeting", "projecting", "driving", "future", "plan", "predict", "may" and si ...

FORWARD LOOKING STATEMENTS NON-GAAP DISCLOSURE Certain statements and information included in this press release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements that look forward in time or express management's beliefs, expectations, hopes or strategies. In particular, such statements include, without limitation: that we are cautiously optimistic and that we've reached a turning point in t ...

Novocure Q3 2025 earnings Thursday, October 30, 2025 Confidential © 2024 © 2025 NovocuNovocu re GmbH re GmbH 1 forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potent ...

Q3 2025 Performance Highlights - Total net revenue increased by 2% to $314 million compared to $307 million in Q3 2024[11] - SUBLOCADE net revenue increased by 15% to $219 million compared to $191 million in Q3 2024[11] - Adjusted EBITDA increased by 14% to $120 million compared to $105 million in Q3 2024[11] Financial Guidance Update - Total net revenue guidance raised to $1180 million - $1220 million, a 1% increase compared to previous guidance[34] - SUBLOCADE net revenue guidance raised to $825 million - $845 million, a 10% increase compared to previous guidance[34] - Adjusted EBITDA guidance raised to $400 million - $420 million, a 15% increase compared to previous guidance[34] Strategic Initiatives - The company is executing Phase I of the Indivior Action Agenda, focusing on generating momentum[13, 42] - Expect at least $150 million in Non-GAAP operating expense savings in 2026[17, 35] - U S SUBLOCADE YTD net revenue growth of 7% to $561 million compared to $524 million[17]